Ongoing Clinical Trials for Supraventricular Tachycardia
There is currently 1 ongoing clinical trial investigating new treatment options for supraventricular tachycardia. This trial is testing a nasal spray medication called etripamil for children aged 6 to 18 years who experience episodes of rapid heart rate. The study is being conducted in multiple European countries and aims to evaluate how quickly and effectively this treatment can restore normal heart rhythm during an episode.
Clinical trial locations
- Germany
- Netherlands
- Spain
Study of Etripamil Nasal Spray for Children with Paroxysmal Supraventricular Tachycardia (Ages 6-18)
This trial is investigating a nasal spray medication called etripamil as a treatment for children experiencing episodes of paroxysmal supraventricular tachycardia, a condition where the heart suddenly starts beating very fast. The study is being conducted in Germany, Spain, and the Netherlands.
Main inclusion criteria:
- Children aged 6 to under 18 years old (the study has two age groups: 12 to under 18 years for Part 1, and 6 to under 12 years for Part 2)
- Body mass index between the 5th and 85th percentiles for age and sex
- Documented history of paroxysmal supraventricular tachycardia confirmed by an electrocardiogram or heart monitoring device
- If the patient previously had an ablation procedure to treat this condition, there must be proof that episodes continued after the procedure
- Females who can become pregnant must have a negative pregnancy test and use adequate birth control methods throughout the study
- Written consent from parents or guardians, and agreement from the child to participate
Main exclusion criteria:
- Children who do not have paroxysmal supraventricular tachycardia
- Children outside the age range of 6 to under 18 years
- Children who belong to vulnerable populations that may need special protection
Focus and goal of the trial:
The main goal of this study is to test whether a single dose of etripamil nasal spray can effectively stop an episode of rapid heartbeat and return the heart to its normal rhythm within 15 minutes. The medication works as a calcium channel blocker, which means it blocks certain signals in the heart that cause it to beat too fast. The nasal spray form allows the medication to work quickly and is easy for children to use during an episode.
Participants will receive the nasal spray when they experience a spontaneous episode of rapid heartbeat. After using the spray, they will be closely monitored to see how quickly their heart rate returns to normal. The study team will also check vital signs like heart rate and blood pressure, watch for any side effects, and determine whether any additional medical help is needed. A follow-up visit will be scheduled to assess the overall response to treatment.
Investigational drug:
The medication being tested is etripamil nasal spray. It is delivered through the nose using a special device that ensures the correct dose is given. Etripamil belongs to a class of medications called calcium channel blockers, which help slow down the heart rate by blocking certain electrical signals in the heart.
Summary
Currently, there is one clinical trial actively recruiting children with supraventricular tachycardia. This trial focuses on testing an innovative nasal spray treatment that could provide quick relief during episodes of rapid heartbeat. The study spans three European countries—Germany, Spain, and the Netherlands—and is divided into two age groups to ensure the medication is evaluated safely and effectively for both younger and older children.
The trial represents an important step in developing more convenient and rapid-acting treatments for this heart condition. The nasal spray approach may offer advantages over traditional methods, as it can be self-administered during an episode and works quickly to restore normal heart rhythm. Families interested in participating should note the specific age requirements and the need for documented medical history of the condition.